title: Importance of minimal residual disease testing during the second year of disease: still no answer?
authors.forename: Maurizio
authors.initials: M
authors.lastname: Aricò
authors.forename: Valentino
authors.initials: V
authors.lastname: Conter
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Valsecchi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Masera
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology*; D018572:Disease-Free Survival; D006801:Humans; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000188:drug therapy*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents